Moderna Shares Climb 16% After $2.5B Patent Settlement Deal
Moderna shares surged 15.99% after the company agreed to pay $2.5 billion to Arbutus Biopharma and Genevant Sciences to resolve a four-year lipid nanoparticle patent dispute. Moderna will incur a $950 million charge in Q1 and may pay up to $1.3 billion upon the Federal Circuit appeal decision.
1. Settlement Agreement and Payment Terms
Moderna reached a $2.5 billion settlement with Arbutus Biopharma and Genevant Sciences to resolve patent infringement claims over lipid nanoparticle technology. The deal calls for a $950 million lump-sum payment in Q3 and up to $1.3 billion contingent on the Federal Circuit’s decision.
2. Q1 Charge and Cash Position
The company expects to record a $950 million charge in the first quarter related to the settlement. After the payment, Moderna anticipates ending the year with $4.5 billion to $5 billion in cash and cash equivalents.
3. Appeal Process and Potential Refund
If the Federal Circuit upholds liability under Section 1498, Moderna will pay the remaining $1.3 billion within 90 days of the decision. Should Moderna prevail in further proceedings, Arbutus and Genevant will refund the full payment plus interest.